Verona Pharma plc diskutieren
Verona Pharma plc (NASDAQ: VRNA) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $68.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock, up previously from $42.00.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at HC Wainwright from $60.00 to $75.00. They now have a "buy" rating on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at Wells Fargo & Company from $74.00 to $93.00. They now have an "overweight" rating on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $80.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) is now covered by analysts at Cowen Inc. They set a "buy" rating on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) is now covered by analysts at TD Cowen. They set a "buy" rating and a $100.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at HC Wainwright from $75.00 to $85.00. They now have a "buy" rating on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at Wells Fargo & Company from $93.00 to $107.00. They now have an "overweight" rating on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at HC Wainwright from $85.00 to $90.00. They now have a "buy" rating on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at Cantor Fitzgerald from $90.00 to $100.00. They now have an "overweight" rating on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at Jefferies Financial Group Inc. from $95.00 to $110.00. They now have a "buy" rating on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma PLC American Depositary Share (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at Roth Capital. They now have a $116.00 price target on the stock, up previously from $92.00.
Ratings data for VRNA provided by MarketBeat
Verona Pharma PLC American Depositary Share (NASDAQ: VRNA) had its price target raised by analysts at Wells Fargo & Company from $107.00 to $138.00. They now have an "overweight" rating on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma PLC American Depositary Share (NASDAQ: VRNA) had its price target raised by analysts at Piper Sandler from $76.00 to $160.00. They now have an "overweight" rating on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma PLC American Depositary Share (NASDAQ: VRNA) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $170.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $100.00 price target on the stock.
Ratings data for VRNA provided by MarketBeat
Neueste Beiträge
B__Riley in WAVE Life Sciences Ltd diskutieren